AzTrials
AzTrials

DexmedetomidineNCT07523438

Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery

A study testing high dex group and low dex group in people with Dexmedetomidine and Emergence Agitation, run by Alexandria University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Read more about this study

Who is it for?
Ages 3 to 6 years
Conditions the study is for
Dexmedetomidine, Emergence Agitation
What is being tested?
high dex group and low dex group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 siteEgypt
Study dates
6 Apr 2026to 15 Oct 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 6 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Age: 3-6 years, both sexes
  • ASA physical status class I , II.

Who cannot join

  • history of neurological and psychiatric disease
  • body mass index > 20 kg m-2
  • allergy to dexmedetomidine
  • patients on medical treatment which has any sedative effect
  • mentally retarded children

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Alexandria University

    Alexandria

Other trials in Egypt

About this study

Official title: Effect of Two Different Doses of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery , A Randomized Clinical Trial

Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg /kg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg/kg

Read the detailed description

Strabismus surgery is typically performed under general anesthesia in pediatric patients. Pediatric patients undergoing strabismus surgery often experience emergence delirium (ED), with rates ranging from 40-86%.(1) ED includes confusion, crying, non-purposeful aggressive movements, and inconsolability during the early stages of recovery from general anesthesia (GA). Adverse effects of ED include increased risk of suture dehiscence, accidental removal of intravenous catheters, self-injury, longer postanesthesia care unit (PACU) stay, and undesirable postoperative behavior.(2,3) Preschool age, preoperative anxiety, pain, otorhinolaryngologic and ocular surgery, certain anesthetic drugs, and rapid awakening from anesthesia are all risk factors for ED.(4) Strabismus surgery is also strongly related to these characteristics. Our hospital performs numerous strabismus operations on preschool children daily. Preoperative anxiety affects up to 60% of young children undergoing surgery and can lead to ED.(5,6) Pharmacological medications have been used to lessen the prevalence of ED. Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort.(7,8, 9) Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg /kg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg/kg

Aim of the work:

The present study aims to compare the effect of use of two different doses of intranasal dexmedetomidine on incidence of emergence agitation after strabismus surgery.

Primary outcome:

  • Incidence of emergence agitation using pediatric anesthesia emergence delirium ( PAED) scale.

Secondary outcomes:

  • Incidence of intraoperative hemodynamic changes: bradycardia and hypotension
  • Postoperative pain score
  • Modified Yale Preoperative Anxiety Scale (mYPAS) upon separation from parents
  • PACU discharge time

Patients :

Study settings:

This study will be conducted in ophthalmology department, Alexandria university hospitals.

Study design:

Double blind, randomized, prospective study

Sample size calculation:

The required sample size has been calculated using the G*power 3.1.1.9.7 Med Calc Software is a corporate member of the American Statistical Association. Member of the International Association of Statistical Computing.(1) and on dependent of chi square test of incidence of agitation, to conduct this study regarding a previous studies carried by Li et al. (2024), was used to predict the different measurement in our study.

Assuming an alpha of 0.05 and power of study 80.0%, the beta error was 0.05 and effect size (p) 0.3, A typical advice is to reject the null hypothesis H0 if the corresponding p-value smaller than 0.05.

The minimum sample size was calculated to be 143 sample, The sample size estimation formula yields the minimum number of subjects required to meet statistical significance for a given hypothesis. However, in an actual study, subject dropout may occur during the study, so in order to satisfy all the number of subjects desired by the researcher, the total number of subjects considering the dropout rate must be calculated so that more subjects can be enrolled. If 'n' is the number of samples calculated according to the formula and 'dr' is the dropout rate, then the adjusted sample size 'N' is given by: N = n / (1 - dr).

The minimum sample size was calculated to be 150 patients, 75 patients in each group after adding the number of patients may be dropout

Study population:

All patients will be randomized 1:1 using a sealed envelope method. Patients will be divided into two equal groups:

Group 1 (high DEX group): 75 patients will receive 3 mcg/kg intranasal dexmedetomidine 45minutes before surgery

Group 2 (low DEX group): 75 patients will receive 2 mcg/kg intranasal dexmedetomidine 45minutes before surgery

Methods:

Preoperative evaluation and preparation:

During preoperative visit, evaluation of patients will be carried out through proper history taking, clinical examination and routine laboratory investigations.

Pre-anesthetic preparation and premedication:

All children will fast 8 h for any solid food, 6 h for milk, and 2 h for clear liquid. All of the patients will be brought to the holding area 45min before the surgery and will be treated according to the group assignment. Intranasal dexmedetomidine will be given to all patients using MAD Nasal intranasal atomization device.

After the application of standard monitoring, including blood pressure, electrocardiography, pulse oximetry and capnography, general anesthesia will be started by tidal volume inhalation induction with 8% sevoflurane and 5 L/min 100% oxygen. IV access will be obtained, and an appropriately sized laryngeal tube will be inserted when a suitable anesthetic depth was obtained. Then, 1 mcg/kg fentanyl will be administered, and the sevoflurane concentration will be adjusted to 2-4% to maintain anesthesia. Spontaneous breathing will be maintained during surgery. If the PETCO2 will be more than 50 mmHg, assisted ventilation will be conducted. At the end of the surgery, sevoflurane will be turned off, and after dressing of the eye and while patients still in the deep level of anesthesia LMA will be removed and patients will be transferred to PACU.

Being tested
high dex group, low dex group
Keywords
Dexmedetomidine, emergence agitation, strabismus surgery
Medical subject headings
Emergence Delirium

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • high dex groupOther

    Also called group 1

    patients will receive 3 mcg/kg intranasal dexmedetomidine 45minutes before surgery

  • low dex groupOther

    Also called group 2

    patients will receive 2 mcg/kg intranasal dexmedetomidine 45minutes before surgery

Study groups in NCT07523438
Study groupRoleWhat they receive
high dex groupOtherpatients will receive 3 mcg/kg intranasal dexmedetomidine 45minutes before surgery
Receives: Other: high dex group
low dex groupOtherpatients will receive 2 mcg/kg intranasal dexmedetomidine 45minutes before surgery
Receives: Other: low dex group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of emergence agitation

    pediatric anesthesia emergence delirium ( PAED) scale.

    Measured: postoperative day 1

Secondary outcomes (3)
  1. Incidence of intraoperative hemodynamic changes

    bradycardia and hypotension

    Measured: postoperative day 1

  2. Modified Yale Preoperative Anxiety Scale (mYPAS) upon separation from parents

    mYPAS

    Measured: postoperative day1

  3. PACU discharge time

    minutes

    Measured: postoperative day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Apr 2026
  2. Study start6 Apr 2026
  3. Primary completion6 Oct 2026
  4. Study completion15 Oct 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
150 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07523438
Sponsor's protocol ID
0307780
Status last verified
Oct 2026
First submitted
5 Apr 2026
Last updated
22 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Chiang FW, Chang JL, Hsu SC, Hsu KY, Chu KC, Huang CJ, Bai CH, Chen C, Hsu CW, Hsu YP. Dexmedetomidine use in pediatric strabismus surgery: A systematic review and meta-analysis. PLoS One. 2020 Oct 12;15(10):e0240553. doi: 10.1371/journal.pone.0240553. eCollection 2020.

    PubMed 33045022

Questions about this trial

What is this clinical trial studying?

A study testing high dex group and low dex group in people with Dexmedetomidine and Emergence Agitation, run by Alexandria University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of emergence agitation (time frame: postoperative day 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07523438, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in